Follow the people · Insider
Isaac Barchas
Isaac Barchas files insider transactions with the SEC as a director of Immunome (IMNM). We hold 9 disclosed purchases and sales filed since 10 September 2021, 9 of them in the last 90 days.
- Files forIMNM
- Disclosed buys and sells9 in all, 9 in the last 90 days
- Last disclosure12 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 27 October 2023 — 12 August 2026Director · Immunome (IMNM)16 Form 4 lines · source: SEC Form 4
- Filed 9 September 2021 — 9 September 2021Other role · TMC the metals Co (TMC)2 Form 4 lines · source: SEC Form 4
Everything they disclosed
18 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 10,125 shares of ImmunomeSEC Form 412 August 2026Common Stock · traded 10 August 2026 · filed 12 August 2026
- ▼ sold on the open market 62,291 shares of ImmunomeSEC Form 412 August 2026Common Stock · traded 11 August 2026 · filed 12 August 2026
- ▼ sold on the open market 11,048 shares of ImmunomeSEC Form 412 August 2026Common Stock · traded 12 August 2026 · filed 12 August 2026
- ▼ sold on the open market 20,840 shares of ImmunomeSEC Form 410 August 2026Common Stock · traded 6 August 2026 · filed 10 August 2026
- ▼ sold on the open market 15,248 shares of ImmunomeSEC Form 410 August 2026Common Stock · traded 7 August 2026 · filed 10 August 2026
- ▼ sold on the open market 83,094 shares of ImmunomeSEC Form 47 July 2026Common Stock · traded 6 July 2026 · filed 7 July 2026
- ▼ sold on the open market 16,906 shares of ImmunomeSEC Form 47 July 2026Common Stock · traded 7 July 2026 · filed 7 July 2026
- ▼ sold on the open market 101,050 shares of ImmunomeSEC Form 42 July 2026Common Stock · traded 30 June 2026 · filed 2 July 2026
- ▼ sold on the open market 75,665 shares of ImmunomeSEC Form 42 July 2026Common Stock · traded 2 July 2026 · filed 2 July 2026
- ▼ sold on the open market 24,335 shares of ImmunomeSEC Form 42 July 2026Common Stock · traded 2 July 2026 · filed 2 July 2026
- was granted 9,897 shares of Immunome (a derivative holding)SEC Form 412 June 2026Director Stock Option (right to buy) · traded 10 June 2026 · filed 12 June 2026
- ▼ sold on the open market 371,949 shares of ImmunomeSEC Form 423 December 2025Common Stock · traded 22 December 2025 · filed 23 December 2025
- ▼ sold on the open market 11,251 shares of ImmunomeSEC Form 423 December 2025Common Stock · traded 22 December 2025 · filed 23 December 2025
- was granted 18,864 shares of Immunome (a derivative holding)SEC Form 412 June 2025Director Stock Option (right to buy) · traded 10 June 2025 · filed 12 June 2025
- was granted 11,333 shares of Immunome (a derivative holding)SEC Form 418 June 2024Stock option (right to buy) · traded 13 June 2024 · filed 18 June 2024
- was granted 41,538 shares of Immunome (a derivative holding)SEC Form 431 October 2023Stock option (right to buy) · traded 27 October 2023 · filed 31 October 2023
- exercised options over 30,000 shares of TMC the metals Co (a derivative holding)SEC Form 410 September 2021Class B ordinary shares · traded 9 September 2021 · filed 10 September 2021
- exercised options over 30,000 shares of TMC the metals CoSEC Form 410 September 2021Common Shares · traded 9 September 2021 · filed 10 September 2021
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.